[{"Assets_0_Q3_USD":370964000.0,"CommonStockSharesOutstanding_0_Q3_shares":55410000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-60689000.0,"NetIncomeLoss_1_Q3_USD":-59433000.0,"NetIncomeLoss_3_Q3_USD":-165338000.0,"StockholdersEquity_0_Q3_USD":-13445000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":12838000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":44633000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20181108"}]